摘要伊马替尼(IM)以及二代酪氨酸激酶抑制剂(TKI)的问世不仅彻底改革了慢性髓系白血病(CML)的治疗模式,也成为其他肿瘤发病机制和治疗研究的范例.IM可使90%以上的慢性期患者获得血液学缓解,80%以上的患者获得遗传学完全缓解(CCyR)及主要分子学缓解(MMoR),明显延长其无病生存期,使CML自然病程大为改观.然而,也存在目前难以克服的缺点:TKI并非疾病基因清除剂,对CML干细胞不敏感,获得CCyR/MMoR者仍需长期持续服用,小部分患者发生抗药或不耐受.现阶段的TKI仍是根治CML的起始.

abstractsImatinib and the second generation tyrosine kinase inhibitors(TKI) not only have revolutionized the management of patients with CML,but also become a model for the development of novel targeting agents in treating malignancies. Under IM treatment.more than 90%CML-CP patients could achieve complete hematologic remission,and more than 80% patients could achieve CCyR/MMoR.,the event free survival at 6-7 years were around 80%.resulting in a major change in the natural history of CML.Nevetherless, TKI cannot eliminate the bcr-abl fusion gene or CML stem cells.the patients have to take the medicine continuously or for life long,More than 10%patients developing resistance Or intolerance are also problematic.The available TKI are preferable choice for treatment of CML